Rossari Biotech Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/0vpm3k7woep34x5kjgs09eed.pdf

Key Takeaways


The Consolidation Story: Why Reported Revenue Understates Growth

Ketan Sablok: "The request would be that the ideal way to now start looking at the numbers is on a consolidated level because certain part of the margin will remain in Rossari and certain part of the margin will remain in the subsidiary."

Segment Performance: HPPC Absorbs a Hit, Textiles Lags, AHN Surges

SegmentTrendCommentary
HPPC▬ ResilientLost one large customer (zero sales in Q4 vs a significant chunk in Q4 last year), yet sales were maintained through smaller detergent clients and a new HUL engagement across two plants. Now 70% of consolidated sales, up from 50% two years ago.
Textiles▼ WeakDegrew overall; sequential growth of 10% in Q4 came from new product additions, but underlying demand remains sluggish and unpredictable. Recovery expected only in H2 FY24.
AHN▲ StrongYear-end revenue of ₹81.2 crore driven by new customer additions and an aggressive entry into vitamins and minerals. Management is bullish and targets doubling revenue in two to three years.
Tristar (consolidated)▲ Growth27% like-to-like growth despite European export pressure; new Rossari-sourced customers compensated for the decline.
Ketan Sablok: "Textile has been acting crazy over the last year. So, every time we think that the worst is over, it really doesn't happen. But currently, this is what the understanding is."

Margin Walk: A One-Time Settlement and Export Pressure Weighed on Q4

Sunil Chari: "We learnt a lesson from FY2021-22 and FY2022-23 that we will not do any forward provisions and we do not do any long contracts with our customers... Similarly, Forex, we have never hedged, and we will never hedge also."

New Product Pipeline and Strategic Initiatives


Guidance & Commitments

CommitmentSpecificsTimeline
Consolidated EBITDA growth20% growth in absolute EBITDA over FY23 consolidated EBITDA (internal target)FY24
Bottom-line growth30% growth projected in internal budgetFY24
HPPC large customer loss recoveryFully cover the revenue loss from the exited accountWithin a couple of quarters
Textile demand recoveryDemand uptick expectedH2 FY24
AHN revenue doublingDouble AHN revenue from current base (~₹125 crore)Next 2–3 years
Unitop full acquisitionAcquire remaining stake to make Unitop 100% ownedAugust 2023
Merger completionRossari, Unitop, and Tristar as one consolidated legal entityBy 31st March 2024
Vitamin premix facilityStart generating meaningful salesLatter half of Q2 / Q3 FY24
Capex₹40–50 crore per yearFY24 and FY25
Asset turns4–5x on a consolidated basisFY24
Interest costSlightly lower than FY23FY24
Bio-surfactant launchIntroduce new bio-based surfactant productA few months

Key Metrics

MetricQ4 FY23
Consolidated revenue₹406.5 crore, up from ₹389.3 crore in Q3 FY23
Standalone revenue₹263.6 crore, up 11.3% QoQ from ₹236.9 crore in Q3 FY23
Consolidated gross margin30%, maintained YoY despite 7% revenue decline
Consolidated EBITDA₹54.6 crore, vs ₹54.2 crore in Q3 FY23; includes ₹2.5–3 crore one-time settlement impact
Consolidated EBITDA margin~13.4%, EBITDA grew 4% YoY
Consolidated PAT₹29 crore, vs ₹25.7 crore in Q3 FY23
Standalone EBITDA₹35.8 crore, vs ₹31.9 crore in Q3 FY23
Standalone PAT₹23.1 crore, vs ₹17.5 crore in Q3 FY23
FY23 consolidated revenue₹1,655.9 crore, up 11.7% YoY
FY23 consolidated EBITDA₹122.7 crore, vs ₹122.8 crore in FY22; margin 12.6%
FY23 consolidated PAT₹107.3 crore, vs ₹97.7 crore in FY22
FY23 gross margin29%, vs 25% in FY22
FY23 EBITDA margin12.6%, vs 12.4% in FY22
HPPC segment FY23 revenue₹1,157 crore, 70% of consolidated revenue
TSC segment FY23 revenue₹373.2 crore, 23% of consolidated revenue
AHN segment FY23 revenue₹125.7 crore, 7% of consolidated revenue
Unitop FY23 revenue₹554 crore, vs ₹454 crore in FY22; EBITDA ₹81 crore vs ₹69 crore
Tristar FY23 revenue₹209 crore, vs ₹164 crore in FY22; EBITDA ₹18 crore vs ₹17 crore
Unitop and Tristar combined FY23 revenue₹763.2 crore, EBITDA ₹98.5 crore; revenue growth of 23% and 13% respectively since FY2022
FY23 exports₹380 crore, vs ₹264 crore in FY22
Consolidated net cash₹77 crore as of March 2023
Cash and cash equivalents₹69.8 crore as of March 2023
Net cash flow from operating activities FY23₹152.4 crore
FY23 depreciation₹62.9 crore, increased due to amortization of fair valuation on subsidiary consolidation
FY23 interest cost₹22.3 crore; includes accounting entry for M&A deferred consideration
Capacity utilization50–55% across most plants
Internal EBITDA growth target20% growth in consolidated EBITDA (absolute amount) for FY24
Bottom-line growth projection30% (per management's internal budget, in response to analyst suggesting 25%)
Capex guidance FY24₹40–50 crore
Tristar one-time settlement impact₹2.5–3 crore, booked in other expenses, impacted Q4 consolidated EBITDA
Net outgo for final Tristar tranche~₹17 crore, funded through internal accruals; Tristar now 100% subsidiary as of 12 April 2023